Kos Parmaceuticals News
Most Popular Kos Parmaceuticals Story
Biotech entrepreneur turns talents to venture fund
The Wall Street Journal offers an in-depth look at Michael Jaharis, a noted biotech entrepreneur who recently sold Kos Pharmaceuticals to Abbott for $4.2 billion. Jaharis has launched Vatera Capital,... Read more...
Latest Headlines
- August 15, 2007
- November 8, 2006
- November 5, 2006
- September 21, 2006
- December 15, 2005
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
